Treatment with anti-interleukin-6 receptor antibody ameliorates intestinal polyposis in ApcMin/+ mice under high-fat diet conditions
-
- Yaoita Takao
- Department of Gastroenterology, Yamagata University Faculty of Medicine
-
- Sasaki Yu
- Department of Gastroenterology, Yamagata University Faculty of Medicine
-
- Yokozawa Junji
- Department of Integrative Genomics, Tohoku Medical Megabank Organization
-
- Sato Takeshi
- Department of Gastroenterology, Yamagata University Faculty of Medicine Division of Endoscopy, Yamagata University Hospital
-
- Kanno Nana
- Department of Gastroenterology, Yamagata University Faculty of Medicine
-
- Sakuta Kazuhiro
- Department of Gastroenterology, Yamagata University Faculty of Medicine
-
- Yagi Makoto
- Department of Gastroenterology, Yamagata University Faculty of Medicine
-
- Yoshizawa Kazuya
- Department of Gastroenterology, Yamagata University Faculty of Medicine
-
- Iwano Daisuke
- Department of Gastroenterology, Yamagata University Faculty of Medicine
-
- Nagino Ko
- Yamagata City Hospital Saiseikan
-
- Nomura Eiki
- Department of Gastroenterology, Yamagata University Faculty of Medicine
-
- Abe Yasuhiko
- Department of Gastroenterology, Yamagata University Faculty of Medicine
-
- Nishise Shoichi
- Department of Gastroenterology, Yamagata University Faculty of Medicine
-
- Takeda Hiroaki
- Department of Gastroenteorogy, Yamagata Prefectural Central Hospital
-
- Kawata Sumio
- Hyogo Prefectural Nishinomiya Hospital
-
- Ueno Yoshiyuki
- Department of Gastroenterology, Yamagata University Faculty of Medicine
書誌事項
- タイトル別名
-
- Treatment with Anti-Interleukin-6 Receptor Antibody Ameliorates Intestinal Polyposis in <i>Apc</i><sup><i>Min/+</i></sup> Mice under High-Fat Diet Conditions
この論文をさがす
抄録
The prevalence of colorectal malignancies is increasing in the world. The parallel increase of metabolic syndrome gives a speculation between these two conditions, although the precise mechanism is still unclear. Interleukin-6 (IL-6) is a cytokine known to correlate with obesity and serve as a proinflammatory adipokine. In the present study, we investigated the effect of IL-6 signaling blockade on intestinal polyp formation in obesity using a mouse model of adenomatous polyposis coli (Apc). Male C57BL/6J-ApcMin/+ mice were fed a high-fat diet from 5 weeks of age, and the overweight mice thus obtained were given a weekly intraperitoneal injection of anti-mouse IL-6 receptor antibody (MR16-1) from 6 to 15 weeks of age, while control mice received IgG or phosphate-buffered saline (PBS). The total number of intestinal polyps was significantly decreased in the MR16-1-injected group (53.1 ± 6.8) relative to the control groups (PBS-injected, 81.3 ± 6.1; rat IgG-injected, 74.7 ± 4.8, p = 0.01), and in particular the number of polyps larger than 2 mm in diameter was markedly decreased. In addition, the mean diameter of polyps in the MR16-1-injected group was significantly smaller than that in the control groups. On the other hand, no significant differences in body weight, epididymal fat pad mass, or the plasma levels of glucose, insulin and triglyceride were observed among the three groups. Thus, treatment with anti-IL-6 receptor antibody suppressed polyp growth in obese ApcMin/+ mice fed the high-fat diet. We suggest that IL-6 signaling may be responsible for the obesity-associated colorectal tumorigenesis.
収録刊行物
-
- The Tohoku Journal of Experimental Medicine
-
The Tohoku Journal of Experimental Medicine 235 (2), 127-134, 2015
東北ジャーナル刊行会